Cargando…

Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy

BACKGROUND: Inhibitors of immune checkpoints have shown little effect in clinical trials involving glioma patients. Here, we explored novel targets for use in future treatments. Previous studies showed the sialic acid-binding Ig-like lectin (Siglec) family to have a specific role in immunosuppressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Guan-Zhang, Zhang, Ke-Nan, Wang, Zheng, Hu, Hui-Min, Wang, Zhi-Liang, Huang, Ruo-Yu, Jiang, Hao-Yu, Zhai, You, Feng, Yue-Mei, Chang, Yuan-Hao, Li, Ren-Peng, Wu, Fan, Zeng, Fan, Jiang, Tao, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885574/ https://www.ncbi.nlm.nih.gov/pubmed/31819511 http://dx.doi.org/10.2147/OTT.S223406

Ejemplares similares

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas
por: Pan, Changqing, et al.
Publicado: (2021)

High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy
por: He, Fei, et al.
Publicado: (2021)

Normalization cancer immunotherapy: blocking Siglec-15!
por: Cao, Guangchao, et al.
Publicado: (2019)

Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle
por: Ren, Xiubao
Publicado: (2019)

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy
por: Yu, Yingyan, et al.
Publicado: (2023)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
por: Wang, Jun, et al.
Publicado: (2019)

A pan‐cancer blueprint of genomics alterations and transcriptional regulation of Siglecs, and implications in prognosis and immunotherapy responsiveness
por: Mei, Song, et al.
Publicado: (2023)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Siglec-15 Is an Immune Suppressor and Potential Target for Immunotherapy in the Pre-Metastatic Lymph Node of Colorectal Cancer
por: Du, Hang, et al.
Publicado: (2021)

Emerging phagocytosis checkpoints in cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas
por: Wang, Hesong, et al.
Publicado: (2022)

Classification of diffuse lower‐grade glioma based on immunological profiling
por: Wu, Fan, et al.
Publicado: (2020)

Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
por: Wang, Yuqing, et al.
Publicado: (2022)

Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy
por: Liu, Xiaodi, et al.
Publicado: (2023)

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
por: Wang, Yuchen, et al.
Publicado: (2022)

Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
por: Wang, Feihu, et al.
Publicado: (2020)

Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
por: Shi, Tao, et al.
Publicado: (2018)

Immunotherapy with heat shock protein 96 to treat gliomas
por: Li, Chunzhao, et al.
Publicado: (2020)

Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy
por: Zhou, Ying, et al.
Publicado: (2022)

Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy
por: Zhang, Yixiao, et al.
Publicado: (2020)

Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
por: Xu, Hao, et al.
Publicado: (2022)

Metabolic checkpoints and novel approaches for immunotherapy against cancer
por: Li, Yiming, et al.
Publicado: (2021)

Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer
por: Liu, Zhi Bing, et al.
Publicado: (2020)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer
por: Hu, Yun, et al.
Publicado: (2023)

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
por: Zhao, Binghao, et al.
Publicado: (2022)

Blocking siglec-10(hi) tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
por: Xiao, Nan, et al.
Publicado: (2021)

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
por: Zhang, Wenjing, et al.
Publicado: (2021)

Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma
por: Chen, Yujia, et al.
Publicado: (2023)

The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy☆
por: Yang, Liping, et al.
Publicado: (2012)

A novel gene signature based on five immune checkpoint genes predicts the survival of glioma
por: Zhang, Wei, et al.
Publicado: (2021)

Immunotherapy for malignant glioma
por: Suryadevara, Carter M., et al.
Publicado: (2015)

Immunotherapies for Malignant Glioma
por: Boussiotis, Vassiliki A., et al.
Publicado: (2017)

CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy
por: Barkal, Amira A, et al.
Publicado: (2019)

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Qiu, Hui, et al.
Publicado: (2021)

Systematic analysis of the necroptosis index in pan-cancer and classification in discriminating the prognosis and immunotherapy responses of 1716 glioma patients
por: Ma, Shuai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hg99viu8q1u7djktfe38aljmoo